{"id":"W4411027651","doi":"10.1200/jco.2025.43.17_suppl.lba1000","title":"Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Fulvestrant; Medicine; Estrogen receptor; Human Epidermal Growth Factor Receptor 2; Internal medicine; Breast cancer; Oncology; Epidermal growth factor receptor; Cancer; Metastatic breast cancer; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002640002,0.0003090049,0.001707383,0.00009436643,0.0001031385,0.00001872145,0.0006142791,0.0004698664,0.00004630712],"category_scores_gemma":[0.004656729,0.0002079515,0.0007896923,0.0003653446,0.0006604051,0.00003556876,0.000145581,0.0007872476,0.000001703578],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001831186,"about_ca_system_score_gemma":0.001856002,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002603424,"about_ca_topic_score_gemma":0.0002857309,"domain_scores_codex":[0.9928087,0.00266474,0.003367135,0.0004584982,0.0003566275,0.0003443215],"domain_scores_gemma":[0.9956174,0.0006818878,0.002489596,0.0003348789,0.0006688295,0.0002073673],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7007567,0.01839165,0.08264516,0.0001480317,0.003018538,0.00008961002,0.0005233226,0.00007996866,0.0762407,0.0008864349,0.006983058,0.1102369],"study_design_scores_gemma":[0.6531025,0.01954118,0.1553026,0.0008089155,0.0005717116,0.00008982037,0.0009124929,0.00003592456,0.1581154,0.001005934,0.009830041,0.0006835037],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886746,0.0005607646,0.0001095405,0.006716881,0.001255254,0.001775579,0.0004489772,0.000006434011,0.0004520107],"genre_scores_gemma":[0.9971561,0.0008356159,0.0008576609,0.0004804044,0.0004337405,0.00008298053,0.00002147355,0.00001621747,0.0001158],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1095533,"threshold_uncertainty_score":0.8480017,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03190532910319258,"score_gpt":0.4072173557020049,"score_spread":0.3753120265988124,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}